No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis
Jie Yuan, Yang Peng, Fa‐Bao Hao, Yaqin Wang, Chunrui Wang, Guo‐Chao Zhong
Abstract
<0.01). In conclusion, TDF is similar to entecavir in reducing HCC incidence among treatment-naïve CHB patients. Heterogeneous results of included studies may result from their disparity in follow-up length. Our findings should be treated with caution and need to be further confirmed.
Topics & Concepts
EntecavirTenofovirHepatocellular carcinomaChronic hepatitisMedicineInternal medicineHepatitis BGastroenterologyOncologyMeta-analysisCarcinomaVirologyVirusHuman immunodeficiency virus (HIV)LamivudineHepatitis B Virus StudiesHepatitis C virus researchLiver Disease Diagnosis and Treatment